WallStSmart
ALC

Alcon AG

NYSE: ALC · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$72.81
-3.44% today

Updated 2026-04-29

Market cap
$36.39B
P/E ratio
36.77
P/S ratio
3.50x
EPS (TTM)
$1.98
Dividend yield
0.48%
52W range
$72 – $99
Volume
1.5M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Alcon AG (ALC) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$72.81
Consensus
$89.38
+22.76%
2030 Target
$335.52
+360.82%
DCF
$90.63
+12.40% MoS
12 analysts:
4 Buy4 Hold2 Sell

Management guidance

No specific quantified revenue targets provided by CEO David J. Endicott in recent filings or earnings calls. Company maintains commitment to organic growth strategy following termination of LENSAR and STAAR acquisitions, focusing on innovation in cataract surgery systems and vision care expansion.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$566.66
$14.1B Rev × 20x P/S
Base case (2030)
$335.52
$14.1B Rev × 12x P/S
Bear case (2030)
$223.68
$14.1B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$9.5B$9.9B$10.4B$11.2B$12.0B$12.6B$13.3B$14.1B
Revenue growth—4.8%4.9%8.0%6.4%5.7%5.5%5.5%
EPS$2.74$2.90$3.06$3.40$3.93$4.35$4.78$5.25
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$268.42$290.78$305.70$320.61$335.52

Catalysts & risks

Growth catalysts
+ Clareon TruPlus IOL launch (April 2026) - expanded monofocal/toric portfolio driving surgical growth
+ PRECISION7 one-week replacement contact lens market penetration in vision care
+ Systane product line extensions and dry eye market expansion driven by screen time trends
+ Organic growth execution following failed M&A (LENSAR, STAAR) - demonstrates capital discipline
+ Aging global population driving elective cataract procedures and vision care demand
Key risks
- Surgical segment weakness - Q4 2025 showed -2% revenue decline in surgical category due to delayed elective procedures in Europe and US inventory adjustments
- 10% ongoing royalty obligation on Hydrus Microstent revenue through November 2028 ($34M patent verdict) - reduces surgical profitability
- Geopolitical headwinds - potential US tariffs on medical devices and European procedure delays impact both segments
- Failed acquisition strategy - two consecutive merger terminations (STAAR, LENSAR) suggest execution challenges in inorganic growth
- Competitive pressure from STAAR Surgical in premium IOL segment and other vision care competitors

Methodology

Alcon AG's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 12 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.